Abstract: A technique includes providing at least one service blueprint to orchestrate application programming interfaces to manage the lifecycle of at least one cloud service.

Abstract: A technique includes providing at least one service blueprint to orchestrate application programming interfaces to manage the lifecycle of at least one cloud service.

Abstract: The present disclosure relates to antiviral compositions and methods. Methods for using the antiviral compositions for inhibiting replication of viruses and treatment of viral diseases are also described. The present disclosure additionally relates to compositions and methods for enhancing a drug’s efficacy by combining the drug with a mammalian protease inhibitor such as a cathepsin inhibitor. Methods for using the combinations for treatment of disease are described.

Abstract: A nanoparticle complex for delivery to cells comprising an RNA interference agent and a delivery vehicle comprised of a liposome and peptide. The peptide may be transmembrane, at least part of which is located external to the liposome. The delivery vehicle is used to deliver the RNA interference agent to cells. The RNA interference agent may target the activity of E3 ubiquitin ligase Itch. The complex may be used to treat chemotherapy resistant tumours and/or cancers. Also related compositions, combination, kit, methods and uses thereof.

Abstract: A technique includes providing at least one service blueprint to orchestrate application programming interfaces to manage the lifecycle of at least one cloud service.

Abstract: A technique includes providing at least one service blueprint to orchestrate application programming interfaces to manage the lifecycle of at least one cloud service.

Abstract: A technique includes providing at least one service blueprint to orchestrate application programming interfaces to manage the lifecycle of at least one cloud service.

Abstract: A technique includes providing at least one service blueprint to orchestrate application programming interfaces to manage the lifecycle of at least one cloud service.

Abstract: A method of instantiating a topology-based service using a blueprint, includes, with a topology designer, modeling the blueprint as a topology, with a resource offering manager, associating a number of policies and a number of lifecycle management actions (LCMAs) with a number of nodes within the topology, and with a lifecycle management (LCM) engine, instantiating the topology based on the policies and LCMAs.

Abstract: A system includes an application blueprint to characterize a given application to enable lifecycle management of the given application on a cloud. An infrastructure blueprint is provided to characterize cloud infrastructure resources on the cloud and enable lifecycle management of the cloud infrastructure resources. A binding manager binds the application blueprint and the infrastructure blueprint to generate an aggregate blueprint based on the application blueprint and the infrastructure blueprint, wherein the aggregate blueprint enables the given application to utilize an instance of provisioned cloud resources specified by the infrastructure blueprint for lifecycle management on the cloud.

Abstract: A technique includes providing a service blueprint associated with a multitenant service to manage the lifecycle of a set of at least one existing cloud service. The blueprint is associated with recipes to orchestrate application programming interfaces to manage the lifecycle.

Abstract: A technique includes providing a service blueprint to manage the lifecycle of at least one hybrid cloud service and orchestrate application programming interfaces across different cloud technologies.

Abstract: A technique includes providing at least one service blueprint to orchestrate application programming interfaces to manage the lifecycle of at least one cloud service.

Abstract: The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of —OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein the D ring of the steroidal ring system is substituted by a group R2 of the formula -L-R3, wherein L is an optional linker group and R3 is selected from groups which are or which comprise one of a nitrite group, an alcohol, an ester, an ether, an amine and an alkene, provided that when R3 is or comprises an alcohol, L is present; and wherein the A ring of the steroidal ring system is substituted at position 2 or 4 with a group R4, wherein R4 is a hydrocarbyl group.